COVID-19 Clinical Trials in San Antonio

Showing 1-20 of 157 trials

NE3107 in Adults With Neurological Symptoms of Long COVID

NCT06847191

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. Researchers will compare NE3107 to a placebo (a look-alike substance that contains no drug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID. Participants will: * Take NE3107 or a placebo twice daily for 84 days * Visit the clinic 5 times for checkups and tests and have a follow up phone call

Long COVID

BioVie Inc.203 participantsStarted Apr 2025

Palo Alto, California, United States • San Francisco, California, United States • Aurora, Colorado, United States +17 more locations

COMPLETEDPhase 3< 1 mile

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

NCT05815498

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).

COVID-19

ModernaTX, Inc.13,553 participantsStarted Mar 2023

Huntsville, Alabama, United States • Vestavia Hills, Alabama, United States • Chandler, Arizona, United States +227 more locations

NE3107 in Adults With Neurological Symptoms of Long COVID

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

COVID-19 Trials in Other Cities

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies

Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine

Safety and Immunogenicity of NVX-CoV2705

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

Study of VYD2311 for the Prevention of COVID-19

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Understanding the Long-term Impact of COVID on Children and Families

Evaluation of COVID-19 and Flu A/B 3 in 1 Combo Rapid Test

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

Other Conditions in San Antonio